Finally, a phase 2 study will evaluate the efficacy of the anti-PD1 agent camrelizumab combined with the tyrosine kinase inhibitor apatinib in advanced ACC (NCT04318730). This evidence concerns the gene PDCD1 and adrenal cortex carcinoma.